YOLFTbeta
Respiratorius AB

Respiratorius AB

RESP · ST · Healthcare / Biotechnology

1.34SEK+0.10 (+8.10%)

Price History

Full chart

Market Stats

Previous Close1.24
Open1.24
Day Range1.24 – 1.37
52-Week Range1.19 – 3.54
Volume24.28K
Market Cap17.15M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.84
Dividend Yield0.00%
Beta1.67
50-Day Avg2.23
200-Day Avg1.98

About

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Johan Drott Ph.D.
  • Employees0
  • HeadquartersMedicon Village, Lund, Sweden, 223 81, Sweden
  • Websitehttps://www.respiratorius.com

Leadership

  • Mr. Johan Drott Ph.D.Chief Executive Officer · b. 1966

Financials

Income Statement

Currency: SEK2023-12-312024-12-312025-12-31
Total Revenue000
Cost of Revenue-585.29K-484.17K8.55K
Gross Profit585.29K484.17K-8.55K
Operating Expense8.42M8.00M6.94M
Operating Income-7.83M-7.51M-6.95M
EBITDA-4.54M-4.12M-3.54M
Net Income-7.83M-7.57M-6.95M
R&D719.00K381.00K4.31M
Interest Expense2.77K53.59K0

Balance Sheet

Currency: SEK2022-12-312023-12-312024-12-312025-12-31
Total Assets35.75M27.77M31.02M31.92M
Total Liabilities1.42M1.27M920.10K1.31M
Total Equity34.33M26.50M30.10M30.61M
Cash7.55M1.95M7.65M7.36M

Cash Flow

Currency: SEK2020-12-312021-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--2.90M-4.26M-4.60M-3.12M
Capital Expenditure018.33M1.35M864.69K4.63M
Free Cash Flow--21.23M-5.61M-5.46M-7.75M
FCF to OCF-731.75%131.62%118.81%248.71%

Earnings

Report DateSep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------------------------
EPS Actual-1.32-0.91-1.10-1.08-1.01-0.80-0.83-0.93-0.89-1.03-0.97-0.99-0.87-1.05-0.63-0.76-0.73-0.78-0.74-0.74-0.69-0.79-0.63-0.78-0.74-0.67-0.85-0.72-0.73-0.47-1.04-1.15-0.76-0.88-1.05-1.06-0.97-1.12-1.47-2.12-0.43-0.73-0.55-0.40-0.77-0.55-0.57-0.42-0.37-0.39-0.35-0.18-0.21-0.22-0.22
Surprise-------------------------------------------------------
Timing-------------------------------------------------------

Key Statistics & Ratios

Market Cap17.15M
Enterprise Value15.88M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales570.24
Price / Book0.58
EPS-0.84
Book Value3.43
Revenue (TTM)30.07K
Gross Profit (TTM)-4.29M
EBITDA-6.06M
Profit Margin0.00%
Operating Margin-22116.34%
Return on Equity-24.92%
Return on Assets-15.20%
Shares Outstanding7.90M
Shares Float7.26M
Beta1.67
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 27, 20241:100